<scp>FOXP3</scp>+/<scp>CD8</scp>+ ratio associated with aggressive behavior in <scp><i>RUNX3</i></scp>‐methylated diffuse esophagogastric junction tumor
The tumor immune microenvironment is increasingly becoming a key consideration in developing treatment regimens for aggressive cancers, with evidence that regulatory T cells (Tregs) attenuate the antitumor response by interrupting cytotoxic T cells (CD8+). Here, we hypothesized the prognostic relevance of the proportions of Tregs (marked by forkhead box protein 3 [FOXP3]) and CD8+ cells in diffuse, non-Epstein-Barr virus (EBV)/non-microsatellite instability (MSI)-high gastroesophageal adenocarcinomas (GEAs), which are clinically characterized as more aggressive, immunologically inactive tumors as compared with their intestinal counterparts. Cell-count ratios of FOXP3+/CD8+ expression were calculated at the intratumoral region and invasive margin discretely on digital images from 303 chemo-naive non-EBV/non-MSI-high esophagogastric junction (EGJ) adenocarcinomas. A significant modifying prognostic effect of tumor histology was observed between 5-year EGJ cancer-specific survival and the FOXP3+/CD8+ ratio at the invasive margin in pStage I-III tumors (p for interaction = 0.022; hazard ratio [HR] = 8.47 and 95% confidence interval [CI], 2.04-35.19 for high ratio [vs. low] for diffuse; HR = 1.57 and 95% CI, 0.88-2.83 for high ratio [vs. low] for intestinal). A high FOXP3+/CD8+ ratio at the invasive margin was associated with RUNX3 methylation (p = 0.035) and poor prognosis in RUNX3-methylated diffuse histological subtype (5-year EGJ cancer-specific survival, 52.3% for high and 100% for low, p = 0.015). Multiomics data from The Cancer Genome Atlas linked CCL28 with RUNX3-suppressed diffuse histological subtypes of non-EBV/non-MSI-high GEA. Our data suggest that a high FOXP3+/CD8+ ratio at the invasive margin might indicate tumor immune escape via CCL28, particularly in the RUNX3-methylated diffuse histological subtype.
Authors
- Suguru Maruyama (ORCID: https://orcid.org/0000-0002-9926-7463)
- Souya Nunobe (ORCID: https://orcid.org/0000-0003-3012-5632)
- Makiko Yamashita
- Shigehisa Kitano (ORCID: https://orcid.org/0000-0002-4041-8298)
- Kenichi Taguchi (ORCID: https://orcid.org/0000-0002-6753-2795)
- Jun Kanamori (ORCID: https://orcid.org/0000-0001-8113-2184)
- Masayuki Watanabe (ORCID: https://orcid.org/0000-0003-0298-1597)
- Takeshi Sano
- Manabu Takamatsu (ORCID: https://orcid.org/0000-0001-9601-5802)
- Yu Imamura (ORCID: https://orcid.org/0000-0002-0036-0124)
- Eiji Oki (ORCID: https://orcid.org/0000-0002-9763-9366)
- Shinji Mine
- Ikumi Haraguchi
- Akihiko Okamura (ORCID: https://orcid.org/0000-0002-3217-8888)
- Yuichiro Nakashima
- Manabu Yamamoto (ORCID: https://orcid.org/0000-0002-9696-3156)
- Tetsuo Noda
- Tasuku Toihata
Institutions
- Kyushu University (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Juntendo University Hospital (JP)
- Japanese Foundation For Cancer Research (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- Cancer Science
- Published
- 2024-10-23
- DOI
- https://doi.org/10.1111/cas.16373
- Citations
- 3
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Japan Research Foundation for Clinical Pharmacology
- Uehara Memorial Foundation
- Boehringer Ingelheim Japan
- Incyte
- Daiichi-Sankyo
- Eisai
- Astellas Pharma
- Foundation for Promotion of Cancer Research
- Ono Pharmaceutical
- Chugai Pharmaceutical
- Loxo Oncology
- Japan Society for the Promotion of Science